Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade	Last Price	% Change	Price Change
	18.9	-4.06%	-0.80

APLS closed down 4.06 percent on Friday, March 22, 2019, on 3.12 times normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Weak or Absent	Up	Up	Down
See historical APLS trend table...

Date	Alert Name	Type	% Chg
Mar 22	MACD Bearish Signal Line Cross	Bearish	0.00%
Mar 22	Non-ADX 1,2,3,4 Bullish	Bullish Swing Setup	0.00%
Mar 22	Volume Surge	Other	0.00%
Mar 22	Wide Bands	Range Expansion	0.00%
Mar 22	Overbought Stochastic	Strength	0.00%
Mar 21	Non-ADX 1,2,3,4 Bullish	Bullish Swing Setup	-4.06%
Mar 21	NR7	Range Contraction	-4.06%
Mar 21	Inside Day	Range Contraction	-4.06%
Mar 21	Wide Bands	Range Expansion	-4.06%
Mar 21	Overbought Stochastic	Strength	-4.06%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
Mar 16	Apellis Pharmaceuticals Presses On With Late-Stage Studies After Trial Enrollment Pause
Mar 11	Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Mar 11	Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow
Mar 7	KR, RIO among premarket losers
Mar 7	Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
Mar 7	Apellis prices stock offering at $17; shares down 9% premarket
Mar 7	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 6	After Hours Gainers / Losers
Mar 6	Apellis readies $75M equity offering
Mar 6	Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					20.45
Resistance 3 (R3)	20.56	20.17			20.19
Resistance 2 (R2)	20.17	19.77		20.11	20.10
Resistance 1 (R1)	19.53	19.53	19.34	19.42	20.02
Pivot Point	19.14	19.14	19.04	19.08	19.14
Support 1 (S1)	18.50	18.74	18.31	18.39	17.78
Support 2 (S2)	18.11	18.50		18.05	17.70
Support 3 (S3)	17.47	18.11			17.61
Support 4 (S4)					17.36